OFSEP - Publications

2024

Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
Benallegue, N., Rollot, F., Wiertlewski, S., Casey, R., Debouverie, M., Kerbrat, A., De Seze, J., Ciron, J., Ruet, A., Labauge, P., et al. (2024). JAMA Neurol (81). p.273–282

The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years-Protocol, recruitment status, and baseline characteristics
Vukusic, S., Bourre, B., Casey, R., Deiva, K., Guennoc, A.-M., Lebrun-Frenay, C., Leray, E., Rollot, F., Benyahya, L., Girod, C., et al. (2024). Mult Scler (30). p.216–226

Risk factors and prognosis of orotracheal intubation in aquaporin-4-IgG neuromyelitis optica spectrum disorder attacks
Januel, E., Brochard, V., Le Guennec, L., Maillart, E., Louapre, C., Lubetzki, C., Weiss, N., Demeret, S., and Papeix, C. (2024). Ann Intensive Care (14). p.4

2023

Predictors of treatment switching in the Big Multiple Sclerosis Data Network
Spelman, T., Magyari, M., Butzkueven, H., Van Der Walt, A., Vukusic, S., Trojano, M., Iaffaldano, P., Horáková, D., Drahota, J., Pellegrini, F., et al. (2023). Front Neurol (14). p.1274194

Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality
Rollot, F., Uhry, Z., Dantony, E., Vukusic, S., Debouverie, M., Le Page, E., Ciron, J., Ruet, A., De Sèze, J., Zéphir, H., et al. (2023). Neurology (101). p.e2483–e2496

The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers
Brocard, G., Casey, R., Dufay, N., Marignier, R., Michel, L., Hisbergues, M., Ayrignac, X., Lehmann, S., Thouvenot, E., Gallot, G., et al. (2023). Multiple Sclerosis and Related Disorders (77). p.104872

Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder
Demuth, S., Collongues, N., Audoin, B., Ayrignac, X., Bourre, B., Ciron, J., Cohen, M., Deschamps, R., Durand-Dubief, F., Maillart, E., et al. (2023). Neurology (101). p.e438–e450

A study on loss functions and decision thresholds for the segmentation of multiple sclerosis lesions on spinal cord MRI
Hussein, B.R., Meurée, C., Gaubert, M., Masson, A., Kerbrat, A., Combès, B., and Galassi, F. (2023). A study on loss functions and decision thresholds for the segmentation of multiple sclerosis lesions on spinal cord MRI. In 20th IEEE International Symposium on Biomedical Imaging (ISBI 2023), (Cartagena (Colombia), Colombia), p.

Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference
Gavoille, A., Rollot, F., Casey, R., Debouverie, M., Le Page, E., Ciron, J., De Seze, J., Ruet, A., Maillart, E., Labauge, P., et al. (2023). Neurology (100). p.e1296–e1308

The radiologically isolated syndrome: revised diagnostic criteria
Lebrun-Frénay, C., Okuda, D.T., Siva, A., Landes-Chateau, C., Azevedo, C.J., Mondot, L., Carra-Dallière, C., Zephir, H., Louapre, C., Durand-Dubief, F., et al. (2023). Brain p.awad073

Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease
Carra-Dallière, C., Rollot, F., Deschamps, R., Ciron, J., Vukusic, S., Audoin, B., Ruet, A., Maillart, E., Papeix, C., Zephir, H., et al. (2023). Mult Scler (29). p.270–276

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network
Signori, A., Lorscheider, J., Vukusic, S., Trojano, M., Iaffaldano, P., Hillert, J., Hyde, R., Pellegrini, F., Magyari, M., Koch-Henriksen, N., et al. (2023). J Neurol Neurosurg Psychiatry (94). p.23–30

Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study
Wilson, S., Calocer, F., Rollot, F., Fauvernier, M., Remontet, L., Tron, L., Vukusic, S., Le Page, E., Debouverie, M., Ciron, J., et al. (2023). Lancet Reg Health Eur (24). p.100542

Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers
Forsberg, L., Spelman, T., Klyve, P., Manouchehrinia, A., Ramanujam, R., Mouresan, E., Drahota, J., Horakova, D., Joensen, H., Pontieri, L., et al. (2023). Mult Scler J Exp Transl Clin (9). p.20552173231153556

Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study
Marignier, R., Laplaud, D., Zéphir, H., Papeix, C., Leray, E., Amri, E., Piotaix, M., and de Sèze, J. (2023). Front Neurol (14). p.1303874

2022

Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system
Sabathé, C., Casey, R., Vukusic, S., Leray, E., Mathey, G., De Sèze, J., Ciron, J., Wiertlewski, S., Ruet, A., Pelletier, J., et al. (2022). Mult Scler p.13524585221139156

Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients
Lescot, L., Lefort, M., Leguy, S., Le Page, E., Vukusic, S., Edan, G., Kerbrat, A., Lebrun-Frenay, C., De Sèze, J., Laplaud, D.A., et al. (2022). Mult Scler Relat Disord (68). p.104122

Improving the detection of new lesions in multiple sclerosis with a cascaded 3D fully convolutional neural network approach
Salem, M., Ryan, M.A., Oliver, A., Hussain, K.F., and Lladó, X. (2022). Front Neurosci (16). p.1007619

COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients
Leguy, S., Lefort, M., Lescot, L., Michaud, A., Vukusic, S., Le Page, E., Edan, G., Kerbrat, A., Lebrun-Frenay, C., De Sèze, J., et al. (2022). J Neurol (269). p.5571–5581

Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry
Simoneau, G., Jiang, X., Rollot, F., Tian, L., Copetti, M., Guéry, M., Ruiz, M., Vukusic, S., de Moor, C., Pellegrini, F., et al. (2022). Mult Scler J Exp Transl Clin (8). p.20552173221116590

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Roos, I., Malpas, C., Leray, E., Casey, R., Horakova, D., Havrdova, E.K., Debouverie, M., Patti, F., De Seze, J., Izquierdo, G., et al. (2022). Neurology p.10.1212/WNL.0000000000201029

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Lefort, M., Sharmin, S., Andersen, J.B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., et al. (2022a). BMC Med Res Methodol (22). p.155

Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments
Lefort, M., Vukusic, S., Casey, R., Edan, G., Leray, E., and OFSEP investigators (2022b). Eur J Neurol

Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera
El Khoury, Y., Gebelin, M., de Sèze, J., Patte-Mensah, C., Marcou, G., Varnek, A., Mensah-Nyagan, A.-G., Hellwig, P., and Collongues, N. (2022). Int J Mol Sci (23). p.2791

Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study
Demuth, S., Guillaume, M., Bourre, B., Ciron, J., Zephir, H., Sirejacob, Y., Kerbrat, A., Lebrun-Frenay, C., Papeix, C., Michel, L., et al. (2022). J Neuroinflammation (19). p.62

Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal
Rollot, F., Couturier, J., Casey, R., Wiertlewski, S., Debouverie, M., Pelletier, J., De Sèze, J., Labauge, P., Ruet, A., Thouvenot, E., et al. (2022). Neurotherapeutics

Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients
Lefort, M., Le Corre, G., Le Page, E., Rizzato, C., Le Port, D., Michel, L., Kerbrat, A., Leray, E., and Edan, G. (2022c). Rev Neurol (Paris) p.S0035-3787(22)00043-1

Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study
Papeix, C., Castelnovo, G., Leray, E., Coustans, M., Levy, P., Visy, J.-M., Kobelt, G., Lamy, F., Allaf, B., Heintzmann, F., et al. (2022). Neurol Ther

2021

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
Sharmin, S., Lefort, M., Andersen, J.B., Leray, E., Horakova, D., Havrdova, E.K., Alroughani, R., Izquierdo, G., Ozakbas, S., Patti, F., et al. (2021). CNS Drugs (35). p.1217–1232

Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review
Poncet-Megemont, L., Pereira, B., Rollot, F., Sormani, M.P., Clavelou, P., and Moisset, X. (2021). Mult Scler p.13524585211052400

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
Lebrun-Frénay, C., Rollot, F., Mondot, L., Zephir, H., Louapre, C., Le Page, E., Durand-Dubief, F., Labauge, P., Bensa, C., Thouvenot, E., et al. (2021). JAMA Netw Open (4). p.e2128271

A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica
Giovannelli, J., Ciron, J., Cohen, M., Kim, H.-J., Kim, S.-H., Stellmann, J.-P., Kleiter, I., McCreary, M., Greenberg, B.M., Deschamps, R., et al. (2021). Ann Clin Transl Neurol (8). p.2025–2037

Cumulative effects of therapies on disability in relapsing multiple sclerosis
Rollot, F., Casey, R., Leray, E., Debouverie, M., Edan, G., Wiertlewski, S., Vukusic, S., and Laplaud, D.-A. (2021a). Mult Scler (27). p.1760–1770

Determinants of therapeutic lag in multiple sclerosis
Roos, I., Leray, E., Frascoli, F., Casey, R., Brown, J.W.L., Horakova, D., Havrdova, E.K., Debouverie, M., Trojano, M., Patti, F., et al. (2021a). Mult Scler (27). p.1838–1851

Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network
Iaffaldano, P., Lucisano, G., Butzkueven, H., Hillert, J., Hyde, R., Koch-Henriksen, N., Magyari, M., Pellegrini, F., Spelman, T., Sørensen, P.S., et al. (2021). Mult Scler (27). p.1543–1555

Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Roos, I., Leray, E., Casey, R., Horakova, D., Havrdova, E., Izquierdo, G., Madueño, S.E., Patti, F., Edan, G., Debouverie, M., et al. (2021b). Neurology (97). p.e869–e880

The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies
Andersen, J.B., Sharmin, S., Lefort, M., Koch-Henriksen, N., Sellebjerg, F., Sørensen, P.S., Hilt Christensen, C.C., Rasmussen, P.V., Jensen, M.B., Frederiksen, J.L., et al. (2021). Mult Scler Relat Disord (53). p.103012

Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study
Vukusic, S., Ionescu, I., Cornu, C., Bossard, N., Durand-Dubief, F., Cotton, F., Durelli, L., Marignier, R., Gignoux, L., Laplaud, D.-A., et al. (2021a). Mult Scler (27). p.1458–1463

Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort
Rollot, F., Fauvernier, M., Uhry, Z., Vukusic, S., Bossard, N., Remontet, L., Leray, E., and OFSEP Investigators (2021b). Neurology (97). p.e403–e413

MRI to detect and localize the area postrema in multiple sclerosis: The role of 3D-DIR and 3D-FLAIR
Farges, V., Hannoun, S., Benini, T., Marignier, R., and Cotton, F. (2021). J Neuroimaging (31). p.701–705

Clinical failure of natalizumab in multiple sclerosis: Specific causes and strategy
Guery, D., Marignier, R., Durand-Dubief, F., Lavie, C., Pique, J., Guerrier, O., and Vukusic, S. (2021). Rev Neurol (Paris) p.S0035-3787(21)00583-X

Untreated patients with multiple sclerosis: A study of French expert centers
Moisset, X., Fouchard, A.-A., Pereira, B., Taithe, F., Mathey, G., Edan, G., Ciron, J., Brochet, B., De Sèze, J., Papeix, C., et al. (2021). Eur J Neurol (28). p.2026–2036

Update on brain MRI for the diagnosis and follow-up of MS patients
Brisset, J.-C., Vukusic, S., Cotton, F., and Imaging Group of the “Observatoire francais de la sclérose en plaques” (2021). Presse Med (50). p.104067

Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease
Ameli, R., Guttmann, C.R.G., Prieto, J.C., Rollot, F., Palotai, M., Vukusic, S., Marignier, R., Cotton, F., Group Members for OFSEP Imaging Working Group, COPIL of OFSEP, et al. (2021). J Neuroradiol (48). p.170–175

Comparison of SimoaTM and EllaTM to assess serum neurofilament-light chain in multiple sclerosis
Gauthier, A., Viel, S., Perret, M., Brocard, G., Casey, R., Lombard, C., Laurent-Chabalier, S., Debouverie, M., Edan, G., Vukusic, S., et al. (2021a). Ann Clin Transl Neurol (8). p.1141–1150

MRI findings in blinded trials should be available to treating physicians - Yes
Vukusic, S., and Lebrun-Frenay, C. (2021). Mult Scler (27). p.812–813

Comparison of SimoaTM and EllaTM to assess serum neurofilament‐light chain in multiple sclerosis
Gauthier, A., Viel, S., Perret, M., Brocard, G., Casey, R., Lombard, C., Laurent‐Chabalier, S., Debouverie, M., Edan, G., Vukusic, S., et al. (2021b). Ann Clin Transl Neurol (8). p.1141–1150

Assessing long-term effectiveness of MS treatment - a matter of debate
Trojano, M., and Iaffaldano, P. (2021). Nat Rev Neurol (17). p.197–198

Pregnancy with multiple sclerosis
Vukusic, S., Michel, L., Leguy, S., and Lebrun-Frenay, C. (2021b). Rev Neurol (Paris) (177). p.180–194

Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy
Rabasté, S., Cobo-Calvo, A., Nistiriuc-Muntean, V., Vukusic, S., Marignier, R., Cotton, F., and OFSEP, NOMADMUS Study Group (2021). J Neuroradiol (48). p.28–36

Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Cobo-Calvo, A., Ruiz, A., Rollot, F., Arrambide, G., Deschamps, R., Maillart, E., Papeix, C., Audoin, B., Lépine, A.F., Maurey, H., et al. (2021). Ann Neurol (89). p.30–41

Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis
Mathais, S., Moisset, X., Pereira, B., Taithe, F., Ciron, J., Labauge, P., Dulau, C., Laplaud, D., De Seze, J., Pelletier, J., et al. (2021). Neurotherapeutics (18). p.378–386

Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network
Hillert, J., Magyari, M., Soelberg Sørensen, P., Butzkueven, H., Van Der Welt, A., Vukusic, S., Trojano, M., Iaffaldano, P., Pellegrini, F., Hyde, R., et al. (2021). Front Neurol (12). p.647811

Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies
Oh, J., Vukusic, S., Tiel-Wilck, K., Inshasi, J.S., Rog, D., Baker, D.P., Pyatkevich, Y., Poole, E.M., and Vermersch, P. (2021). J Cent Nerv Syst Dis (13). p.11795735211028780

Women’s Health in Multiple Sclerosis: A Scoping Review
Ross, L., Ng, H.S., O’Mahony, J., Amato, M.P., Cohen, J.A., Harnegie, M.P., Hellwig, K., Tintore, M., Vukusic, S., and Marrie, R.A. (2021). Front Neurol (12). p.812147

2020

Association of Pregnancy With the Onset of Clinically Isolated Syndrome
Nguyen, A.-L., Vodehnalova, K., Kalincik, T., Signori, A., Havrdova, E.K., Lechner-Scott, J., Skibina, O.G., Eastaugh, A., Taylor, L., Baker, J., et al. (2020). JAMA Neurol (77). p.1496–1503

Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity score
Lefort, M., Foucher, Y., Lenain, R., Vukusic, S., Edan, G., and Leray, E. (2020). Pharmacoepidemiol Drug Saf (29). p.1680–1688

Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI
Roca, P., Attye, A., Colas, L., Tucholka, A., Rubini, P., Cackowski, S., Ding, J., Budzik, J.-F., Renard, F., Doyle, S., et al. (2020). Diagn Interv Imaging (101). p.795–802

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS: Response to the editor
Vukusic, S., Durand-Dubief, F., and Marignier, R. (2020a). Mult Scler (26). p.1610–1611

Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Roos, I., Leray, E., Frascoli, F., Casey, R., Brown, J.W.L., Horakova, D., Havrdova, E.K., Trojano, M., Patti, F., Izquierdo, G., et al. (2020a). Brain (143). p.2742–2756

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
Maarouf, A., Rico, A., Boutiere, C., Perriguey, M., Demortiere, S., Pelletier, J., Audoin, B., and Under the aegis of OFSEP (2020). Neurol Neuroimmunol Neuroinflamm (7). p.e825

Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event
Lebrun-Frenay, C., Kantarci, O., Siva, A., Sormani, M.P., Pelletier, D., Okuda, D.T., and 10-year RISC study group on behalf of SFSEP, OFSEP (2020). Ann Neurol (88). p.407–417

Relapses During High-Dose Biotin Treatment in Progressive Multiple Sclerosis: a Case-Crossover and Propensity Score-Adjusted Prospective Cohort
Branger, P., Parienti, J.-J., Derache, N., Kassis, N., Assouad, R., Maillart, E., and Defer, G. (2020). Neurotherapeutics (17). p.989–993

Facteurs pronostiques de la première attaque dans des maladies du spectre de la neuromyélite optique et associées à l’anticorps anti-MOG
Guillaume, M. (2020). p.146

Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment
Ouallet, J.-C. (2020). Rev Neurol (Paris) (176). p.500–504

Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes
de Seze, J., and Bigaut, K. (2020). Rev Neurol (Paris) (176). p.497–499

Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients
Calocer, F., Dejardin, O., Kwiatkowski, A., Bourre, B., Vermersch, P., Hautecoeur, P., Launoy, G., and Defer, G. (2020). Mult Scler Relat Disord (40). p.101930

Predictive medicine in multiple sclerosis: A systematic review
Havas, J., Leray, E., Rollot, F., Casey, R., Michel, L., Lejeune, F., Wiertlewski, S., Laplaud, D., and Foucher, Y. (2020). Mult Scler Relat Disord (40). p.101928

Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
Maillart, E., Durand-Dubief, F., Louapre, C., Audoin, B., Bourre, B., Derache, N., Ciron, J., Collongues, N., de Sèze, J., Cohen, M., et al. (2020). J Neuroinflammation (17). p.128

MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No
Cobo-Calvo, A., and Marignier, R. (2020). Mult. Scler. (26). p.274–276

Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: A multicenter cross-sectional study
Cobo-Calvo, Á., d’Indy, H., Ruiz, A., Collongues, N., Kremer, L., Durand-Dubief, F., Rollot, F., Casey, R., Vukusic, S., De Seze, J., et al. (2020). Neurol Neuroimmunol Neuroinflamm (7).

New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions
Brisset, J.-C., Kremer, S., Hannoun, S., Bonneville, F., Durand-Dubief, F., Tourdias, T., Barillot, C., Guttmann, C., Vukusic, S., Dousset, V., et al. (2020). J Neuroradiol

Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France
Vukusic, S., Rollot, F., Casey, R., Pique, J., Marignier, R., Mathey, G., Edan, G., Brassat, D., Ruet, A., De Sèze, J., et al. (2020b). JAMA Neurol (77). p.94–102

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France
Vukusic, S., Casey, R., Rollot, F., Brochet, B., Pelletier, J., Laplaud, D.-A., De Sèze, J., Cotton, F., Moreau, T., Stankoff, B., et al. (2020c). Mult Scler (26). p.118–122

Longitudinal study of functional brain network reorganization in clinically isolated syndrome
Koubiyr, I., Deloire, M., Besson, P., Coupé, P., Dulau, C., Pelletier, J., Tourdias, T., Audoin, B., Brochet, B., Ranjeva, J.-P., et al. (2020). Mult. Scler. (26). p.188–200

Evaluation of efficacy and tolerability of first-line therapies in NMOSD
Poupart, J., Giovannelli, J., Deschamps, R., Audoin, B., Ciron, J., Maillart, E., Papeix, C., Collongues, N., Bourre, B., Cohen, M., et al. (2020). Neurology (94). p.e1645–e1656

NEUROLOGY MS ID#: NEUROLOGY/2020/080531 MS TITLE: Outcome predictors of the first attack in Neuromyelitis Optica Spectrum Disorders and MOG-Associated Disease
Collongues, N.

2019

A Logic-Based Framework Leveraging Neural Networks for Studying the Evolution of Neurological Disorders
Calimeri, F., Cauteruccio, F., Cinelli, L., Marzullo, A., Stamile, C., Terracina, G., Durand-Dubief, F., and Sappey-Marinier, D. (2019). Theory and Practice of Logic Programming p.1–45

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
Cobo-Calvo, A., Sepúlveda, M., Rollot, F., Armangué, T., Ruiz, A., Maillart, E., Papeix, C., Audoin, B., Zephir, H., Biotti, D., et al. (2019a). J Neuroinflammation (16). p.134

Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions
Ayrignac, X., Rigau, V., Lhermitte, B., Vincent, T., de Champfleur, N.M., Carra-Dalliere, C., Charif, M., Collongues, N., de Seze, J., Hebbadj, S., et al. (2019). J. Neurol. (266). p.1743–1755

Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study
Ciron, J., Cobo-Calvo, A., Audoin, B., Bourre, B., Brassat, D., Cohen, M., Collongues, N., Deschamps, R., Durand-Dubief, F., Laplaud, D., et al. (2019). Mult. Scler. p.1352458519849511

Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease
Ameli, R., R G Guttmann, C., Prieto, J.C., Rollot, F., Palotai, M., Vukusic, S., Marignier, R., Cotton, F., and Group Members for OFSEP Imaging Working, COPIL of OFSEP, the NOMADMUS study group. (2019). J Neuroradiol

Caractéristique de la cohorte française des pré syndromes radiologiques isolés (PRE RIS)
Callier, C., Vermersch, P., Durand-Dubief, F., Carra-Dallière, C., Wiertlewski, S., Mondot, L., and Lebrun-Frenay, C. (2019). Revue Neurologique (175). p.S85

Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults
Cobo-Calvo, A., Sepúlveda, M., d’Indy, H., Armangué, T., Ruiz, A., Maillart, E., Papeix, C., Audoin, B., Zephir, H., Biotti, D., et al. (2019b). J. Neurol. (266). p.806–815

Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults
Cobo-Calvo, A., Sepúlveda, M., d’Indy, H., Armangué, T., Ruiz, A., Maillart, E., Papeix, C., Audoin, B., Zephir, H., Biotti, D., et al. (2019c). J. Neurol. (266). p.816

Spatial distribution of multiple sclerosis lesions in the cervical spinal cord
Eden, D., Gros, C., Badji, A., Dupont, S.M., De Leener, B., Maranzano, J., Zhuoquiong, R., Liu, Y., Granberg, T., Ouellette, R., et al. (2019). Brain (142). p.633–646

Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome
Makhani, N., Lebrun, C., Siva, A., Narula, S., Wassmer, E., Brassat, D., Brenton, J.N., Cabre, P., Carra Dallière, C., de Seze, J., et al. (2019a). Mult Scler J Exp Transl Clin (5). p.2055217319836664

Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome
Makhani, N., Lebrun, C., Siva, A., Narula, S., Wassmer, E., Brassat, D., Brenton, J.N., Cabre, P., Carra Dallière, C., de Seze, J., et al. (2019b). Mult Scler J Exp Transl Clin (5). p.2055217319836664

Cranial nerve involvement in patients with MOG antibody–associated disease
Cobo-Calvo, A., Ayrignac, X., Kerschen, P., Horellou, P., Cotton, F., Labauge, P., Vukusic, S., Deiva, K., Serguera, C., and Marignier, R. (2019d). Neurol Neuroimmunol Neuroinflamm (6).

Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases
Codjia, P., Ayrignac, X., Carra-Dalliere, C., Cohen, M., Charif, M., Lippi, A., Collongues, N., Corti, L., De Seze, J., Lebrun, C., et al. (2019). Mult Scler Relat Disord (28). p.109–116

First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre study
Lavandier, N., Bonnan, M., Carra-Dallière, C., Charif, M., Labauge, P., Camdessanche, J.-P., Edan, G., Naudin, A., Brassat, D., Ciron, J., et al. (2019). Mult Scler Relat Disord (28). p.309–312

[Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis]
Zephir, H., Puyade, M., Gueguen, A., Michel, L., Terriou, L., Dive, D., Laureys, G., Mathey, G., Labauge, P., Marjanovic, Z., et al. (2019). Bull Cancer (106). p.S92–S101

Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults
Cobo-Calvo, A., Vukusic, S., and Marignier, R. (2019e). Curr. Opin. Neurol. (32). p.459–466

Myelin oligodendrocyte glycoprotein antibody associated disease: about the importance of diagnostic assays and selection of the target population in retrospective studies
Cobo-Calvo, A., Ruiz, A., and Marignier, R. (2019f). Eur. J. Neurol. (26). p.e58–e59

Efficacy of rituximab in refractory RRMS
Durozard, P., Maarouf, A., Boutiere, C., Ruet, A., Brochet, B., Vukusic, S., Carra-Dalliere, C., Labauge, P., Mathey, G., Debouverie, M., et al. (2019). Mult. Scler. (25). p.828–836

Multiple sclerosis registries in Europe - An updated mapping survey
Glaser, A., Stahmann, A., Meissner, T., Flachenecker, P., Horáková, D., Zaratin, P., Brichetto, G., Pugliatti, M., Rienhoff, O., Vukusic, S., et al. (2019). Mult Scler Relat Disord (27). p.171–178

Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks
Gros, C., De Leener, B., Badji, A., Maranzano, J., Eden, D., Dupont, S.M., Talbott, J., Zhuoquiong, R., Liu, Y., Granberg, T., et al. (2019). Neuroimage (184). p.901–915

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium (2019a). Science (365).

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium (2019b). Science (365).

Multiple sclerosis: effect of beta interferon treatment on survival
Kingwell, E., Leray, E., Zhu, F., Petkau, J., Edan, G., Oger, J., and Tremlett, H. (2019). Brain (142). p.1324–1333

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
Laplaud, D.-A., Casey, R., Barbin, L., Debouverie, M., De Sèze, J., Brassat, D., Wiertlewski, S., Brochet, B., Pelletier, J., Vermersch, P., et al. (2019). Neurology (93). p.e635–e646

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS
Lavie, C., Rollot, F., Durand-Dubief, F., Marignier, R., Ionescu, I., Casey, R., Moreau, T., Tourniaire, P., Hutchinson, M., D’Hooghe, M.B., et al. (2019). Mult. Scler. (25). p.591–600

Classification of Multiple Sclerosis Clinical Profiles via Graph Convolutional Neural Networks
Marzullo, A., Kocevar, G., Stamile, C., Durand-Dubief, F., Terracina, G., Calimeri, F., and Sappey-Marinier, D. (2019). Front Neurosci (13). p.594

The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab
Nicolas, P., Ruiz, A., Cobo-Calvo, A., Fiard, G., Giraudon, P., Vukusic, S., and Marignier, R. (2019). Front Immunol (10). p.2686

2018

First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: a multicentre study
Ouallet, Dr.J.-C. (2018a). Multiple Sclerosis and Related Disorders

Diversité des prises en charge des patients atteints de sclérose en plaques entre régions françaises
Blein, C., Chamoux, C., Reynaud, D., and Lepage, V. (2018a). Revue d’Épidémiologie et de Santé Publique (66). p.385–394

[Care pathway diversity of patients with multiple sclerosis between French regions]
Blein, C., Chamoux, C., Reynaud, D., and Lepage, V. (2018b). Rev Epidemiol Sante Publique (66). p.385–394

Evidence of axonal damage in cerebellar peduncles without T2-lesions in multiple sclerosis
Hannoun, S., Kocevar, G., Durand-Dubief, F., Stamile, C., Naji, A., Cotton, F., Cavallari, M., Guttmann, C.R.G., and Sappey-Marinier, D. (2018a). Eur J Radiol (108). p.114–119

Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome
Koubiyr, I., Deloire, M., Coupé, P., Dulau, C., Besson, P., Moroso, A., Planche, V., Tourdias, T., Brochet, B., and Ruet, A. (2018). Front Neurol (9).

Case Report: Acute Transverse Myelitis after Zika Virus Infection
Neri, V.C., Xavier, M.F., Barros, P.O., Melo Bento, C., Marignier, R., and Papais Alvarenga, R. (2018). Am. J. Trop. Med. Hyg.

Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study
Defer, G., de Seze, J., Bouee, S., Courouve, L., Longin, J., Payet, M., Deleglise, A.S.J., and study group (2018a). Mult Scler Relat Disord (25). p.276–281

Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure
Commowick, O., Istace, A., Kain, M., Laurent, B., Leray, F., Simon, M., Pop, S.C., Girard, P., Améli, R., Ferré, J.-C., et al. (2018). Sci Rep (8). p.13650

“Myelitis migrans”: A rare cause of treatable myelitis
Jaulent, P., Pegat, A., Grosset-Janin, C., Durand-Dubief, F., Vukusic, S., and Marignier, R. (2018a). Rev. Neurol. (Paris)

Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus?
Jaulent, P., Hannoun, S., Kocevar, G., Rollot, F., Durand-Dubief, F., Vukusic, S., Brisset, J.-C., Sappey-Marinier, D., and Cotton, F. (2018b). Eur J Radiol (105). p.204–208

Unusual neurologic presentation of aseptic abscesses syndrome
Nicolas, P., Guerrier, O., Benoit, A., Durand-Dubief, F., Raverot, G., Debarbieux, S., Delteil, C., Vasiljevic, A., Jouanneau, E., Cotton, F., et al. (2018). Neurol Neuroimmunol Neuroinflamm (5). p.e469

Efficacité comparée du Teriflunomide et du Dimethyl-Fumarate : une étude observationnelle française multicentrique
Laplaud, D.-A., Barbin, L., Casey, R., Debouverie, M., Vukusic, S., Labauge, P., Brassat, D., Wiertlewski, S., De Seze, J., Edan, G., et al. (2018). Revue d’Épidémiologie et de Santé Publique (66). p.S201

Conventional and advanced MRI in multiple sclerosis
Louapre, C. (2018). Revue Neurologique (174). p.391–397

Organization of care for multiple sclerosis in France
Derache, N., Dufay, A., and Lebarbey, C. (2018). Rev. Neurol. (Paris) (174). p.475–479

Organization of healthcare in multiple sclerosis
Gignoux, L. (2018). Rev. Neurol. (Paris) (174). p.471–474

Diagnostic value of 3DFLAIR in clinical practice for the detection of infratentorial lesions in multiple sclerosis in regard to dual echo T2 sequences
Hannoun, S., Heidelberg, D., Hourani, R., Nguyen, T.T.T., Brisset, J.-C., Grand, S., Kremer, S., Bonneville, F., Guttmann, C.R.G., Dousset, V., et al. (2018b). Eur J Radiol (102). p.146–151

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study
Cobo-Calvo, A., Ruiz, A., Maillart, E., Audoin, B., Zephir, H., Bourre, B., Ciron, J., Collongues, N., Brassat, D., Cotton, F., et al. (2018). Neurology

Oligoclonal Bands in Spinal Fluid Improve the Specificity of Different MRI Criteria for Dissemination in Space to Predict a First Clinical Event in Children with the Radiologically Isolated Syndrome (S51.002)
Makhani, N., Lebrun, C., Siva, A., Narula, S., Wassmer, E., Brenton, J.N., Brassat, D., Carra-Dalliere, C., Seze, J.D., Dubief, F.D., et al. (2018). Neurology (90). p.S51.002

Efficacité et sécurité d’emploi de l’alemtuzumab à 2 ans : retour sur 150 patients français
Ayrignac, X., De Seze, J., Vukusic, S., Brassat, D., Laplaud, D., Lebrun-Frénay, C., and Labauge, P. (2018). Revue Neurologique (174). p.S155

Formes atypiques de sclérose en plaques et autres affections inflammatoires démyélinisantes idiopathiques du système nerveux central : étude nationale sur 88 cas
Codjia, P., Ayrignac, X., Carra-Dallière, C., Durand-Dubief, F., De Seze, J., Lebrun-Frenay, C., and Labauge, P. (2018). Revue Neurologique (174). p.S100–S101

Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Hacohen, Y., Wong, Y.Y., Lechner, C., Jurynczyk, M., Wright, S., Konuskan, B., Kalser, J., Poulat, A.L., Maurey, H., Ganelin-Cohen, E., et al. (2018). JAMA Neurol (75). p.478–487

Controverse : les traitements de fond modifient-ils le passage en forme secondairement progressive ? Synthèse
Ouallet, J.-C. (2018b). Revue Neurologique (174). p.S180–S181

Landscape of MS patient cohorts and registries: Recommendations for maximizing impact
Bebo, B.F., Fox, R.J., Lee, K., Utz, U., and Thompson, A.J. (2018). Mult Scler (24). p.579–586

Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study
Cabre, P., Mejdoubi, M., Jeannin, S., Merle, H., Plumelle, Y., Cavillon, G., Smadja, D., Marignier, R., and Francophone Society of Multiple Sclerosis and OFSEP investigators (2018). J. Neurol. (265). p.917–925

Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial
Defer, G., Le Caignec, F., Fedrizzi, S., Montastruc, F., Chevanne, D., Parienti, J.-J., and Peyro-Saint-Paul, L. (2018b). Trials (19).

Weekly follow up of acute lesions in three early multiple sclerosis patients using MR spectroscopy and diffusion
Kocevar, G., Stamile, C., Hannoun, S., Roch, J.-A., Durand-Dubief, F., Vukusic, S., Cotton, F., and Sappey-Marinier, D. (2018). J Neuroradiol (45). p.108–113

Cervical spinal cord atrophy
Zeydan, B., Gu, X., Atkinson, E.J., Keegan, B.M., Weinshenker, B.G., Tillema, J.-M., Pelletier, D., Azevedo, C.J., Lebrun-Frenay, C., Siva, A., et al. (2018). Neurol Neuroimmunol Neuroinflamm (5).

Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients
Calocer, F., Dejardin, O., Droulon, K., Launoy, G., and Defer, G. (2018). PLoS ONE (13). p.e0191646

Caractéristique de la cohorte française des syndromes radiologiques isolés (RIS)
Christine Lebrun-Frénay, R., Céline Callier, Patrick Vermersch, Caroline Papeix, Emmanuelle Le Page, Françoise Durand-Dubief, Pierre Labauge, OFSEP, SFSEP (2018). Revue Neurologique (5961). p.S2–S200

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
Ciron, J., Audoin, B., Bourre, B., Brassat, D., Durand-Dubief, F., Laplaud, D., Maillart, E., Papeix, C., Vukusic, S., Zephir, H., et al. (2018). Rev. Neurol. (Paris) (174). p.255–264

The first MICCAI challenge on PET tumor segmentation
Hatt, M., Laurent, B., Ouahabi, A., Fayad, H., Tan, S., Li, L., Lu, W., Jaouen, V., Tauber, C., Czakon, J., et al. (2018). Med Image Anal (44). p.177–195

Demyelinating diseases
Lebrun, C., and de Seze, J. (2018). Rev. Neurol. (Paris) (174). p.355

Quelle utilisation des traitements de fond chez des patients ayant une SEP rémittente en France sur la période 1990–2017 ? Éléments de réponse à partir des données de l’Ofsep
Leray, E., Rollot, F., Casey, R., Roux, J., De Seze, J., Laplaud, D., and Vukusic, S. (2018). Revue Neurologique (5961). p.S2–S200

Human Induced Pluripotent Stem Cell-Derived Astrocytes Are Differentially Activated by Multiple Sclerosis-Associated Cytokines
Perriot, S., Mathias, A., Perriard, G., Canales, M., Jonkmans, N., Merienne, N., Meunier, C., El Kassar, L., Perrier, A.L., Laplaud, D.-A., et al. (2018). Stem Cell Reports (11). p.1199–1210

2017

Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? Comments. Anti-JCV antibody index in multiple sclerosis care
Stankoff, B. (2017). Revue Neurologique (173). p.616–618

Radiologically isolated syndrome in children: Clinical and radiologic outcomes
Makhani, N., Lebrun, C., Siva, A., Brassat, D., Carra Dallière, C., de Seze, J., Du, W., Durand Dubief, F., Kantarci, O., Langille, M., et al. (2017a). Neurol Neuroimmunol Neuroinflamm (4). p.e395

A Comparison of Machine Learning Approaches for Classifying Multiple Sclerosis Courses Using MRSI and Brain Segmentations
Ion-Margineanu, A., Kocevar, G., Stamile, C., M. Sima, D., Durand-Dubief, F., Huffel, S., and Sappey-Marinier, D. (2017). A Comparison of Machine Learning Approaches for Classifying Multiple Sclerosis Courses Using MRSI and Brain Segmentations. pp. 643–651

MOG antibody-related disorders: common features and uncommon presentations
Cobo-Calvo, Á., Ruiz, A., D’Indy, H., Poulat, A.-L., Carneiro, M., Philippe, N., Durand-Dubief, F., Deiva, K., Vukusic, S., Desportes, V., et al. (2017). J. Neurol. (264). p.1945–1955

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders
Montcuquet, A., Collongues, N., Papeix, C., Zephir, H., Audoin, B., Laplaud, D., Bourre, B., Brochet, B., Camdessanche, J.-P., Labauge, P., et al. (2017). Mult. Scler. (23). p.1377–1384

The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility
Consortium, I.M.S.G., Patsopoulos, N.A., Baranzini, S.E., Santaniello, A., Shoostari, P., Cotsapas, C., Wong, G., Beecham, A.H., James, T., Replogle, J., et al. (2017). BioRxiv p.143933

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
Asgari, N., Flanagan, E.P., Fujihara, K., Kim, H.J., Skejoe, H.P., Wuerfel, J., Kuroda, H., Kim, S.H., Maillart, E., Marignier, R., et al. (2017). Neurol Neuroimmunol Neuroinflamm (4). p.e343

Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients
Barros, P.O., Dias, A.S.O., Kasahara, T.M., Ornelas, A.M.M., Aguiar, R.S., Leon, S.A., Ruiz, A., Marignier, R., Araújo, A.C.R.A., Alvarenga, R., et al. (2017). J. Neuroimmunol. (307). p.82–90

An excessive risk of suicide may no longer be a reality for multiple sclerosis patients
Kalson-Ray, S., Edan, G., and Leray, E. (2017). Mult Scler (23). p.864–871

Multiple sclerosis broke my heart
Androdias, G., Bernard, E., Biotti, D., Collongues, N., Durand-Dubief, F., Pique, J., Sanchez, I., Delmas, C., Ninet, J., Marignier, R., et al. (2017). Ann. Neurol. (81). p.754–758

Comparison of MRI Dissemination in Space Criteria for Predicting a First Clinical Event in Children with the Radiologically Isolated Syndrome (S2.001)
Makhani, N., Lebrun, C., Siva, A., Narula, S., Wassmer, E., Brenton, J.N., Dalliere, C.C., Seze, J.D., Dubief, F.D., Langille, M., et al. (2017b). Neurology (88). p.S2.001

Neuromielite ottica acuta (malattia di Devic)
Nicolas, P., and Marignier, R. (2017). EMC - Neurologia (17). p.1–13

Can we discontinue disease-modifying treatments in multiple sclerosis patients? No
Papeix, C. (2017). Revue Neurologique (173). p.41–43

L’OFSEP : du soin à la recherche, améliorer nos connaissances sur la sclérose en plaques
Debard, N., Casey, R., Vukusic, S., and investigateurs de l’OFSEP (2017). La Lettre Du Neurologue

Machine Learning Approach for Classifying Multiple Sclerosis Courses by Combining Clinical Data with Lesion Loads and Magnetic Resonance Metabolic Features
Ion-Mărgineanu, A., Kocevar, G., Stamile, C., Sima, D.M., Durand-Dubief, F., Van Huffel, S., and Sappey-Marinier, D. (2017). Front Neurosci (11). p.398

Neuromyelitis optica and neuromyelitis optica spectrum disorders
Marignier, R., Cobo Calvo, A., and Vukusic, S. (2017). Curr. Opin. Neurol. (30). p.208–215

Multiparametric Non-Negative Matrix Factorization for Longitudinal Variations Detection in White-Matter Fiber Bundles
Stamile, C., Kocevar, G., Cotton, F., Maes, F., Sappey-Marinier, D., and Van Huffel, S. (2017). IEEE J Biomed Health Inform (21). p.1393–1402

2015

Neuromyelitis optica: a positive appraisal of seronegative cases
Bernard-Valnet, R., Liblau, R.S., Vukusic, S., and Marignier, R. (2015). Eur. J. Neurol. (22). p.1511–1518, e82-83

A longitudinal model for variations detection in white matter fiber-bundles
Stamile, C., Kocevar, G., Cotton, F., Hannoun, S., Durand-Dubief, F., Frindel, C., Rousseau, D., and Sappey-Marinier, D. (2015). 2015 International Conference on Systems, Signals and Image Processing (IWSSIP) p.57–60

Does cerebrospinal fluid analysis add predictive value to magnetic resonance imaging for long term irreversible disability in patients with early multiple sclerosis?
Moroso, A., Deloire, M.S.A., Ruet, A., Ouallet, J.-C., Casey, R., and Brochet, B. (2015). Journal of the Neurological Sciences (354). p.51–55

OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol
Cotton, F., Kremer, S., Hannoun, S., Vukusic, S., Dousset, V., and Imaging Working Group of the Observatoire Français de la Sclérose en Plaques (2015a). J Neuroradiol (42). p.133–140

Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis
Vukusic, S., Durand-Dubief, F., Benoit, A., Marignier, R., Frangoulis, B., and Confavreux, C. (2015). Mult. Scler. (21). p.953–955

Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome
Lebrun, C., Forzy, G., Collongues, N., Cohen, M., de Seze, J., and Hautecoeur, P. (2015). Revue Neurologique (171). p.390–393

[Evolution of Devic’s neuromyelitis optica spectrum disorders]
Bernard-Valnet, R., and Marignier, R. (2015). Presse Med (44). p.401–410

Weekly multimodal MRI follow-up of two multiple sclerosis active lesions presenting a transient decrease in ADC
Hannoun, S., Roch, J.-A., Durand-Dubief, F., Vukusic, S., Sappey-Marinier, D., Guttmann, C.R.G., and Cotton, F. (2015). Brain Behav (5). p.e00307

Criteria improving multiple sclerosis diagnosis at the first MRI
Caucheteux, N., Maarouf, A., Genevray, M., Leray, E., Deschamps, R., Chaunu, M.P., Daelman, L., Ferré, J.C., Gout, O., Pelletier, J., et al. (2015). J. Neurol. (262). p.979–987

L’Observatoire français de la sclérose en plaques (OFSEP): établissement d’un protocole commun minimum dans la sclérose en plaques
Cotton, F., Hannoun, S., Kremer, S., Guillaumont, J., and Dousset, V. (2015b). Revue Neurologique (171). p.A65–A66

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study
Leray, E., Vukusic, S., Debouverie, M., Clanet, M., Brochet, B., de Sèze, J., Zéphir, H., Defer, G., Lebrun-Frenay, C., Moreau, T., et al. (2015). PLoS ONE (10). p.e0132033

2014

Microstructural changes in the striatum and their impact on motor and neuropsychological performance in patients with multiple sclerosis
Cavallari, M., Ceccarelli, A., Wang, G.-Y., Moscufo, N., Hannoun, S., Matulis, C.R., Jackson, J.S., Glanz, B.I., Bakshi, R., Neema, M., et al. (2014). PLoS ONE (9). p.e101199

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset
Collongues, N., Marignier, R., Jacob, A., Leite, M.I., Siva, A., Paul, F., Zephir, H., Akman-Demir, G., Elsone, L., Jarius, S., et al. (2014). Mult. Scler. (20). p.1086–1094

2013

Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity
Marignier, R., Bernard-Valnet, R., Giraudon, P., Collongues, N., Papeix, C., Zéphir, H., Cavillon, G., Rogemond, V., Casey, R., Frangoulis, B., et al. (2013). Neurology (80). p.2194–2200

Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study
Cabre, P., Olindo, S., Marignier, R., Jeannin, S., Merle, H., Smadja, D., and Aegis of French National Observatory of Multiple Sclerosis (2013). J. Neurol. Neurosurg. Psychiatry (84). p.511–516

TYSEDMUS : suivi observationnel prospectif des patients atteints de sclérose en plaques et traités par TYSABRI® (natalizumab) dans les bases des données EDMUS en France : données finales à cinq ans
Passante, N. (2013). Revue Neurologique (169). p.A227